Neogenomics (NEO) Share-based Compensation (2010 - 2026)

Neogenomics (NEO) has 17 years of Share-based Compensation data on file, last reported at $8.2 million in Q2 2026.

• Quarterly Share-based Compensation fell 32.73% year-over-year to $8.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $36.2 million (up 15.67% YoY) and the FY2025 annual result came in at $41.3 million, up 23.65% from the prior year.
• Share-based Compensation fell to $8.2 million in Q2 2026, from $9.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $12.2 million in Q2 2025 to a low of $200000.0 in Q2 2024.
• A 5-year average of $7.5 million and a median of $8.0 million in 2025 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2023 — Share-based Compensation sank 60.69% — and 2025, when it soared 6007.0%.
• Tracing NEO's Share-based Compensation over 5 years: stood at $4.7 million in 2022, then soared by 49.9% to $7.0 million in 2023, then gained by 19.14% to $8.3 million in 2024, then declined by 3.43% to $8.0 million in 2025, then rose by 2.16% to $8.2 million in 2026.
• The last three Share-based Compensation figures came in at $8.2 million (Q2 2026), $9.6 million (Q1 2026), and $8.0 million (Q4 2025), per Business Quant data.